Cite
MLA Citation
A.R. Mato et al.. “PHASE I/II STUDY OF UMBRALISIB (TGR‐1202) IN COMBINATION WITH UBLITUXIMAB (TG‐1101) AND PEMBROLIZUMAB IN PATIENTS WITH REL/REF CLL AND RICHTER'S TRANSFORMATION.” Hematological oncology, vol. 37, n.d., pp. 119–120. http://access.bl.uk/ark:/81055/vdc_100086208575.0x00003d